Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (6818)	7/27/1998 4:35:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

opala, I will miss you. You are correct it has not been a pleasant experience to hold XOMA during the past months or years. I do not agree that not halting the trial early means the results are negative, but understand that you will use this point in time to make your own decision regarding XOMA. Before you leave, please let us know the origin of your name.

To: opalapril who wrote (6818)	7/27/1998 5:49:00 PM
From: Bluegreen	Respond to of 17367

Opalapril, for me the experience is just starting. This is EXACTLY the type of situation I love being in. What you need to do is take some time to review the scientific facts. That is the nice thing about science, it is factually based, you know few things in life are like science. This is my plan: If DSMB says continue then I hope stock will go below at least 3 and maybe lower. The lower the better for me and that is when I pounce on it. If there is a halt for approval then I buy at best prices I can. I don't fear safety concerns because of usage of Neuprex so far. Now in my book it is just a matter of someone rigging a trial for Neuprex slick enough to pass FDA ridiculous efficacy parameters. That is why Congress now is looking at why FDA is in the efficacy business anyway especially when we need them more than ever for SAFETY. Think about it, how much of medicine is practiced off label? Seems to work real well without FDA deciding efficacy off label so just carry it one step further and ask why they are involved with efficacy at all for primary indication. Once again Opalapril, as long as the science is there, I keep buying. It is like Peter Lynch saying stay with an investment as long as the story is there. Tough decision to sell Xoma if the story is still ongoing. George, I thought it was your Grandpa Opalapril.

To: opalapril who wrote (6818)	7/27/1998 7:19:00 PM
From: LarryS	Respond to of 17367

In September, regardless of the DSMB decision, I don't believe the trial will end. If they recommend halting that only means that they believe the results are so important they are recommending to move immediately to presenting the results to the FDA, the actual trial won't be halted. Instead of ending the trial in Dec'98 and presenting the information to the FDA in March'99, those dates would be moved up to Oct and Jan because of the recommendation to present the results earlier. Even if XOMA believed they would get approval I think they would continue the trial in case the FDA decides they want more information/results. My hope is the results will be so good in Sept that they continue the trial BUT stop giving patients placibos, since safety is not a problem. Why risk death for patients this season, give them all Neuprex. And include these results if the FDA asks for more information. Opalapril....first two names of the poster or her grandmother's.